Xiaochu Zhang1, Elliot A Stein, L Elliot Hong. 1. Neuroimaging Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21228, USA.
Abstract
BACKGROUND: Although schizophrenia patients are at high risk for tobacco use, the neurobiological basis of this comorbid association is not clear. White matter abnormalities have been described independently in schizophrenia and smoking cohorts. We sought to determine whether smoking and schizophrenia are associated with similar white matter abnormalities that could be biomarkers for the high risk of smoking in schizophrenia. METHODS: Whole brain white matter integrity (fractional anisotropy) was measured in 46 schizophrenia patients (32 smokers and 14 nonsmokers) and 69 healthy age-matched control subjects (48 smokers and 21 nonsmokers). RESULTS: Schizophrenia and smoking status were independently and additively associated with reduced fractional anisotropy in left anterior thalamic radiation/anterior limb of the internal capsule, and significant fractional anisotropy decreases were identified in the bilateral uncinate fasciculus/inferior fronto-occipital fasciculus in schizophrenia and the left prefrontal area in smoking status separately. CONCLUSIONS: Common and distinct patterns of impaired white matter are associated with schizophrenia and smoking. Particularly, the anatomic congruence of an additive white matter abnormality in the anterior thalamic radiation/anterior limb of the internal capsule suggests that this abnormal fiber connectivity between frontal cortex and striatum/thalamus may be a biomarker for the increased comorbid smoking in schizophrenia patients.
BACKGROUND: Although schizophreniapatients are at high risk for tobacco use, the neurobiological basis of this comorbid association is not clear. White matter abnormalities have been described independently in schizophrenia and smoking cohorts. We sought to determine whether smoking and schizophrenia are associated with similar white matter abnormalities that could be biomarkers for the high risk of smoking in schizophrenia. METHODS: Whole brain white matter integrity (fractional anisotropy) was measured in 46 schizophreniapatients (32 smokers and 14 nonsmokers) and 69 healthy age-matched control subjects (48 smokers and 21 nonsmokers). RESULTS:Schizophrenia and smoking status were independently and additively associated with reduced fractional anisotropy in left anterior thalamic radiation/anterior limb of the internal capsule, and significant fractional anisotropy decreases were identified in the bilateral uncinate fasciculus/inferior fronto-occipital fasciculus in schizophrenia and the left prefrontal area in smoking status separately. CONCLUSIONS: Common and distinct patterns of impaired white matter are associated with schizophrenia and smoking. Particularly, the anatomic congruence of an additive white matter abnormality in the anterior thalamic radiation/anterior limb of the internal capsule suggests that this abnormal fiber connectivity between frontal cortex and striatum/thalamus may be a biomarker for the increased comorbid smoking in schizophreniapatients.
Authors: Marek Kubicki; Carl-Fredrik Westin; Stephan E Maier; Melissa Frumin; Paul G Nestor; Dean F Salisbury; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley; Martha E Shenton Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Leslie K Jacobsen; John H Krystal; W Einar Mencl; Michael Westerveld; Stephen J Frost; Kenneth R Pugh Journal: Biol Psychiatry Date: 2005-01-01 Impact factor: 13.382
Authors: Serge A Mitelman; Yuliya Torosjan; Randall E Newmark; Jason S Schneiderman; King-Wai Chu; Adam M Brickman; M Mehmet Haznedar; Erin A Hazlett; Cheuk Y Tang; Lina Shihabuddin; Monte S Buchsbaum Journal: Schizophr Res Date: 2007-02-27 Impact factor: 4.939
Authors: Leslie K Jacobsen; D Cyril D'Souza; W Einar Mencl; Kenneth R Pugh; Pawel Skudlarski; John H Krystal Journal: Biol Psychiatry Date: 2004-04-15 Impact factor: 13.382
Authors: Stefano Marenco; Jason L Stein; Antonina A Savostyanova; Fabio Sambataro; Hao-Yang Tan; Aaron L Goldman; Beth A Verchinski; Alan S Barnett; Dwight Dickinson; José A Apud; Joseph H Callicott; Andreas Meyer-Lindenberg; Daniel R Weinberger Journal: Neuropsychopharmacology Date: 2011-09-28 Impact factor: 7.853
Authors: Matthew Hudkins; Joseph O'Neill; Marc C Tobias; George Bartzokis; Edythe D London Journal: Psychopharmacology (Berl) Date: 2012-01-04 Impact factor: 4.530
Authors: Krista M Wisner; Joshua Chiappelli; Anya Savransky; Feven Fisseha; Laura M Rowland; Peter Kochunov; L Elliot Hong Journal: Brain Imaging Behav Date: 2020-04 Impact factor: 3.978
Authors: Dana Anderson; Babak A Ardekani; Katherine E Burdick; Delbert G Robinson; Majnu John; Anil K Malhotra; Philip R Szeszko Journal: Bipolar Disord Date: 2013-06-25 Impact factor: 6.744
Authors: Hanneke van Ewijk; Annabeth P Groenman; Marcel P Zwiers; Dirk J Heslenfeld; Stephen V Faraone; Catharina A Hartman; Marjolein Luman; Corina U Greven; Pieter J Hoekstra; Barbara Franke; Jan Buitelaar; Jaap Oosterlaan Journal: Hum Brain Mapp Date: 2014-12-06 Impact factor: 5.038